ISCT2024 Poster: Adapting T cells for the Tumor Microenvironment (TME) During Manufacturing for Improved Anti-Tumor Potency
ISCT2024 Poster – Adapting T cells for the Tumor Microenvironment (TME) During Manufacturing for Improved Anti-Tumor Potency Adapting T cells for the Tumor Microenvironment (TME) During Manufacturing for Improved Anti-Tumor Potency Enhancing T-cell fitness in solid tumors is vital for effective therapies. In this poster, AmplifyBio uses the Avatar incubator to create low-oxygen, high-pressure […]
ISCT2024 Poster: AmplifyBio TCR Specificity Platform: Better Off-target Assessment for Safer TCR-based Therapies
ISCT2024 Poster – AmplifyBio TCR Specificity Platform: Better Off-target Assessment for Safer TCR-based Therapies AmplifyBio TCR Specificity Platform: Better Off-target Assessment for Safer TCR-based Therapies AmplifyBio’s TCR Specificity Platform enhances TCR-T cell therapy development by integrating peptide positional flexibility assessment, comprehensive human proteome searches, tissue gene expression, in silico machine learning predictions, and cell-based assays. […]
Mitigating Risk, Maximizing Quality: AmplifyBio’s Data Integrity Journey
By: Amy Adams, Systems Analyst At AmplifyBio, we understand the critical role data integrity plays in achieving successful outcomes. While spreadsheets are a cornerstone of many businesses, they can introduce errors due to their inherent ease of use and accessibility. This is especially concerning in GxP-regulated environments, where compliance with 21 CFR Part 11 is […]
AmplifyBio Expands Capacity for Advanced Therapy Pathology Services
An integral part of AmplifyBio’s vision is to continuously assess the needs of our clients and invest in valuable, differentiating, and translational capabilities to serve the needs of advanced therapy development. An example of that commitment comes from the growth of cell and gene therapy and other biologic modalities, causing a notable shift in the […]
AmplifyBio Streamlines CGT Discovery, Safety, and Manufacturing Services with Benchling Cloud
[West Jefferson, Ohio] — AmplifyBio, a leading provider of advanced therapy discovery, safety, and manufacturing services, announces the implementation of Benchling’s cloud-based unified scientific data platform across all service areas. The integration of Benchling further signifies AmplifyBio’s commitment to streamlining workflows, enhancing collaboration, and ultimately accelerating cell and gene therapy development and commercialization for its clients. Benchling […]
ASGCT2024 Poster: Validation of a Spectral Flow Cytometry Platform for Use in a GxP Environment
ASGCT2024 Poster – Validation of a Spectral Flow Cytometry Platform for Use in a GxP Environment Validation of a Spectral Flow Cytometry Platform for Use in a GxP Environment This AmplifyBio poster evaluates a spectral flow cytometry method for use in regulated environments (GxP). The researchers qualified a specific instrument (Cytek® Aurora) using reference samples […]
ASGCT2024 Poster: Qualification of a Preclinical to Phase I ELISpot Assay for AAV Immune Monitoring
ASGCT2024 Poster – Qualification of a Preclinical to Phase I ELISpot Assay for AAV Immune Monitoring Qualification of a Preclinical to Phase I ELISpot Assay for AAV Immune Monitoring This AmplifyBio poster describes a new method for identifying immune responses to AAV gene therapy using an ELISpot assay. This method is sensitive and requires fewer […]
ASGCT2024 Poster: 2024 Data Pipeline
ASGCT2024 Poster – 2024 Data Pipeline Validated Solution for High Throughput Analyses with Flexible Mods for Custom Assay Design This poster discusses the challenges of analyzing complex data in cell and gene therapies, as traditional methods can be time-consuming and resource-intensive. In it, AmplifyBio proposes a new, custom-designed solution to automate data analysis using ETL […]
ASGCT2024 Poster: AmplifyBio Non-viral Gene Editing Platform
ASGCT2024 Poster – AmplifyBio Non-viral Gene Editing (NVGE ™) Platform AmplifyBio Non-viral Gene Editing (NVGE™) Platform This AmplifyBio poster describes their non-viral gene editing platform (NVGE™) for engineering T cells for adoptive cell therapy. This platform can be utilized to knock out multiple genes and express transgenes in a single step at both research and […]
SQA 2024 Presentation: Building Resilient GxP Quality Processes to Support Business Needs
AmplifyBio presented in the Beyond Compliance Specialty track at the Society of Quality Assurance 2024. The presentation, titled “Building Resilient GxP Quality Processes to Support Business Needs,” discusses AmplifyBio’s journey of implementing our eQMS, Veeva, and, more importantly, the evolution of the quality processes behind the system. AmplifyBio’s shift from a compliance culture to a […]
